Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients.
Matteo BrunoAdriana Ionelia ApostolSerena Maria BocciaCarolina Maria SassuSara LardinoCamilla CulcasiDomenica LorussoGiovanni ScambiaAnna FagottiClaudia MarchettiPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
Niraparib dose reduction occurs in almost half of patients within cycles 1-3, although it is significantly more common in the first-line setting. Survival outcomes seem not to be impaired by dose reduction.